• +1-646-491-9876
    • +91-20-67278686

    Search

    Hemophilia A Pipeline Review H1 2017

    Hemophilia A Pipeline Review H1 2017

    • Report Code ID: RW0001799294
    • Category Pharmaceuticals
    • No. of Pages 151
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Hemophilia A - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H1 2017, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.

    Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII) , which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 8, 6, 5, 1, 20, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

    Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders) .
    - The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Hemophilia A - Overview 7
    Hemophilia A - Therapeutics Development 8
    Pipeline Overview 8
    Pipeline by Companies 9
    Pipeline by Universities/Institutes 12
    Products under Development by Companies 13
    Products under Development by Universities/Institutes 16
    Hemophilia A - Therapeutics Assessment 17
    Assessment by Target 17
    Assessment by Mechanism of Action 19
    Assessment by Route of Administration 21
    Assessment by Molecule Type 23
    Hemophilia A - Companies Involved in Therapeutics Development 25
    Alnylam Pharmaceuticals Inc 25
    Amarna Therapeutics BV 25
    Apitope International NV 25
    Bayer AG 26
    BioMarin Pharmaceutical Inc 26
    Bioverativ Inc 27
    Catalyst Biosciences Inc 27
    Chugai Pharmaceutical Co Ltd 28
    CSL Ltd 28
    DBV Technologies SA 29
    Dimension Therapeutics Inc 29
    Emergent BioSolutions Inc 30
    EpiVax Inc 30
    Expression Therapeutics LLC 31
    Green Cross Corp 31
    Idogen AB 32
    Immusoft Corp 32
    Lentigen Technology Inc 32
    mAbxience SA 33
    Novo Nordisk A/S 33
    OPKO Biologics Ltd 34
    Pangen Biotech Inc. 34
    Pfizer Inc 34
    Pharming Group NV 35
    Promethera Biosciences SA 35
    rEVO Biologics Inc 36
    Sangamo Therapeutics Inc 36
    Shire Plc 36
    SK Chemicals Co Ltd 37
    Spark Therapeutics Inc 38
    UniQure NV 38
    XL-protein GmbH 39
    Hemophilia A - Drug Profiles 40
    antihemophilic factor (recombinant) - Drug Profile 40
    antihemophilic factor (recombinant) - Drug Profile 41
    antihemophilic factor (recombinant) - Drug Profile 42
    antihemophilic factor (recombinant) - Drug Profile 43
    antihemophilic factor (recombinant) - Drug Profile 44
    antihemophilic factor (recombinant) - Drug Profile 45
    antihemophilic factor (recombinant) biosimilar - Drug Profile 46
    antihemophilic factor (recombinant) biosimilar - Drug Profile 47
    antihemophilic factor (recombinant) biosimilar - Drug Profile 48
    antihemophilic factor (recombinant) , PEGylated - Drug Profile 49
    antihemophilic factor (recombinant) , pegylated - Drug Profile 54
    antihemophilic factor (recombinant) , porcine sequence - Drug Profile 57
    antihemophilic factor (recombinant) , single chain - Drug Profile 61
    ATXF-8117 - Drug Profile 65
    BAX-888 - Drug Profile 66
    BAY-1093884 - Drug Profile 67
    BIVV-001 - Drug Profile 68
    BMN-270 - Drug Profile 70
    Cell Therapy to Target Coagulation Factor VIII for Hemophilia A - Drug Profile 72
    coagulation factor VIIa (recombinant) - Drug Profile 73
    concizumab - Drug Profile 75
    CSL-689 - Drug Profile 77
    damoctocog alfa pegol - Drug Profile 79
    Deimmunized FVIII - Drug Profile 81
    DTX-201 - Drug Profile 82
    emicizumab - Drug Profile 83
    ET-3 - Drug Profile 86
    fitusiran - Drug Profile 87
    Gene Therapy for Hematological Disorders - Drug Profile 95
    Gene Therapy for Hemophilia A - Drug Profile 96
    Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile 97
    Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile 98
    HepaStem - Drug Profile 99
    IN-3012 - Drug Profile 102
    Kovaltry - Drug Profile 104
    LG-889 - Drug Profile 107
    LR-769 - Drug Profile 108
    marzeptacog alfa - Drug Profile 111
    MG-1113A - Drug Profile 114
    MOD-5014 - Drug Profile 115
    Monoclonal Antibody for Hemophilia A - Drug Profile 118
    PBB-8-IN - Drug Profile 119
    PF-06741086 - Drug Profile 120
    Recombinant Factor VIII Replacement for Hemophilia A - Drug Profile 121
    Recombinant Protein to Inhibit Coagulation Factor XIV for Hemophilia A and Hemophilia B - Drug Profile 122
    Recombinant Protein to Replace Coagulation Factor VIII for Hemophilia A - Drug Profile 123
    Recombinant Proteins for Hemophilia A - Drug Profile 124
    SB-525 - Drug Profile 125
    SEL-201 - Drug Profile 127
    SHP-656 - Drug Profile 128
    SPK-8011 - Drug Profile 130
    SVF-VIIa - Drug Profile 132
    Hemophilia A - Dormant Projects 133
    Hemophilia A - Discontinued Products 135
    Hemophilia A - Product Development Milestones 136
    Featured News & Press Releases 136
    Appendix 146
    Methodology 146
    Coverage 146
    Secondary Research 146
    Primary Research 146
    Expert Panel Validation 146
    Contact Us 146
    Disclaimer 147

    List of Tables

    Number of Products under Development for Hemophilia A, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Hemophilia A - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017
    Hemophilia A - Pipeline by Amarna Therapeutics BV, H1 2017
    Hemophilia A - Pipeline by Apitope International NV, H1 2017
    Hemophilia A - Pipeline by Bayer AG, H1 2017
    Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc, H1 2017
    Hemophilia A - Pipeline by Bioverativ Inc, H1 2017
    Hemophilia A - Pipeline by Catalyst Biosciences Inc, H1 2017
    Hemophilia A - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
    Hemophilia A - Pipeline by CSL Ltd, H1 2017
    Hemophilia A - Pipeline by DBV Technologies SA, H1 2017
    Hemophilia A - Pipeline by Dimension Therapeutics Inc, H1 2017
    Hemophilia A - Pipeline by Emergent BioSolutions Inc, H1 2017
    Hemophilia A - Pipeline by EpiVax Inc, H1 2017
    Hemophilia A - Pipeline by Expression Therapeutics LLC, H1 2017
    Hemophilia A - Pipeline by Green Cross Corp, H1 2017
    Hemophilia A - Pipeline by Idogen AB, H1 2017
    Hemophilia A - Pipeline by Immusoft Corp, H1 2017
    Hemophilia A - Pipeline by Lentigen Technology Inc, H1 2017
    Hemophilia A - Pipeline by mAbxience SA, H1 2017
    Hemophilia A - Pipeline by Novo Nordisk A/S, H1 2017
    Hemophilia A - Pipeline by OPKO Biologics Ltd, H1 2017
    Hemophilia A - Pipeline by Pangen Biotech Inc., H1 2017
    Hemophilia A - Pipeline by Pfizer Inc, H1 2017
    Hemophilia A - Pipeline by Pharming Group NV, H1 2017
    Hemophilia A - Pipeline by Promethera Biosciences SA, H1 2017
    Hemophilia A - Pipeline by rEVO Biologics Inc, H1 2017
    Hemophilia A - Pipeline by Sangamo Therapeutics Inc, H1 2017
    Hemophilia A - Pipeline by Shire Plc, H1 2017
    Hemophilia A - Pipeline by SK Chemicals Co Ltd, H1 2017
    Hemophilia A - Pipeline by Spark Therapeutics Inc, H1 2017
    Hemophilia A - Pipeline by UniQure NV, H1 2017
    Hemophilia A - Pipeline by XL-protein GmbH, H1 2017
    Hemophilia A - Dormant Projects, H1 2017
    Hemophilia A - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Hemophilia A - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Hemophilia A, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Alnylam Pharmaceuticals Inc
    Amarna Therapeutics BV
    Apitope International NV
    Bayer AG
    BioMarin Pharmaceutical Inc
    Bioverativ Inc
    Catalyst Biosciences Inc
    Chugai Pharmaceutical Co Ltd
    CSL Ltd
    DBV Technologies SA
    Dimension Therapeutics Inc
    Emergent BioSolutions Inc
    EpiVax Inc
    Expression Therapeutics LLC
    Green Cross Corp
    Idogen AB
    Immusoft Corp
    Lentigen Technology Inc
    mAbxience SA
    Novo Nordisk A/S
    OPKO Biologics Ltd
    Pangen Biotech Inc.
    Pfizer Inc
    Pharming Group NV
    Promethera Biosciences SA
    rEVO Biologics Inc
    Sangamo Therapeutics Inc
    Shire Plc
    SK Chemicals Co Ltd
    Spark Therapeutics Inc
    UniQure NV
    XL-protein GmbH

    Request for Sample

    Report Url http://www.reportsweb.com//hemophilia-a-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hemophilia-a-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hemophilia-a-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments